Revenue distribution by industries:

• Medical devices: approx. 45%
• Life Sciences: approx. 30%
• Interventional solutions: approx. 25%

TOP 3 markets and their percentage shares:

• USA: approx. 50%
• Europe: approx. 25%
• Asia-Pacific: approx. 15%

Becton, Dickinson and Company (BD) generates the majority of its revenue from the sale of medical devices used in hospitals and clinics worldwide. The Life Sciences division, which includes products for research and diagnostics, also contributes significantly to the revenue. Interventional solutions supporting minimally invasive procedures are a growing area.

The US market is the largest single market for BD, driven by high demand for medical devices and solutions. Europe and the Asia-Pacific region follow, with the latter region offering significant growth potential due to increasing healthcare expenditures and a growing population.

Production Sites: USA, Europe, Asia

Becton, Dickinson and Company (BD) operates a variety of production facilities worldwide. The main production sites are located in the USA, where the company manufactures a large portion of its medical devices and diagnostic products. In addition, BD has significant production capacities in Europe and Asia to meet global demand and ensure logistical efficiency.

This international presence enables BD to efficiently adapt its products to different markets and optimize supply chains. The strategic distribution of production sites also supports the company's innovation capability by providing access to various technological and scientific resources worldwide.

Strategic Focus:

• Innovation Investments: $1.2 billion annually (2025)
• Market Expansion in Emerging Countries: 20% revenue growth in these regions (2024)
• Sustainability Goals: Reduce CO2 emissions by 50% by 2030

Becton, Dickinson and Company (BD) pursues a multi-faceted growth strategy that heavily relies on innovation and geographical expansion. The company invests over a billion dollars annually in research and development to expand its product pipeline and introduce new medical technologies to the market.

Another focus is on expanding in emerging countries, where BD is experiencing significant revenue growth. These markets offer great potential due to the increasing demand for medical products and services.

Additionally, BD has set ambitious sustainability goals to reduce its ecological footprint. These measures are intended not only to decrease environmental impact but also to strengthen the company's long-term competitiveness.

Main raw materials: Plastic resins, stainless steel, glass, electronic components

Main importing countries: China, Germany, Japan, USA

Becton, Dickinson and Company (BD) is heavily dependent on the procurement of specific raw materials necessary for the production of its medical devices and diagnostic products. Among the most important raw materials are plastic resins used in the production of syringes and other medical devices. These are often imported from China and the USA.

Stainless steel and glass are also crucial for the manufacturing of medical instruments and diagnostic devices. These materials are frequently sourced from Germany and Japan, known for their high-quality metal and glass products.

Additionally, BD imports electronic components, essential for many modern medical devices, from these countries as well. The choice of importing countries is based on the availability of high-quality materials and the reliability of supply chains.

Market share: Approx. 25% in the field of medical devices (2024, estimate)

Research & Development (R&D) expenses: 7.5% of revenue (2023)

Patent portfolio: Over 27,000 active patents worldwide (2023)

Becton, Dickinson and Company (BD) possesses a significant competitive advantage based on several factors. The high market share of about 25% in the field of medical devices demonstrates the company's strong market position. This position is supported by continuous investments in research and development, accounting for approximately 7.5% of revenue. This enables BD to develop and introduce innovative products to the market.

The extensive patent portfolio with over 27,000 active patents worldwide protects the company's technological innovations and creates entry barriers for competitors. These patents secure BD a technological edge and strengthen its market position.

In addition, BD benefits from a wide range of products and a global presence, allowing the company to react flexibly to fluctuations in individual markets. The combination of these factors gives BD a sustainable competitive advantage in the medical technology industry.

Institutional investor share: approx. 85% (estimated for 2025)

Insider purchases/sales: No significant transactions in the last 12 months (estimated for 2025)

The institutional investor share in Becton, Dickinson and Company is traditionally high, indicating the trust of large investment funds and institutional investors in the stability and growth potential of the company.

Regarding insider purchases and sales, there have been no significant transactions in the past year, suggesting that the management and other insiders do not expect significant changes in their assessment of the company's value or future development.

These estimates are based on historical trends and general market information, as specific data for 2025 is not available.

Market share of Becton, Dickinson and Company (BDX): 12% (2025, estimated)

Main competitors and their market shares:

1. Medtronic: 15%
2. Johnson & Johnson: 14%
3. Becton, Dickinson and Company (BDX): 12%
4. Thermo Fisher Scientific: 10%
5. Abbott Laboratories: 9%
6. Siemens Healthineers: 8%
7. Roche Diagnostics: 7%
8. GE Healthcare: 6%
9. Philips Healthcare: 5%
10. Danaher Corporation: 4%

Moat of Becton, Dickinson and Company:

Becton, Dickinson and Company (BDX) has a significant moat, mainly supported by its strong brand recognition, extensive product range, and global presence. The company is particularly well positioned in the areas of medical devices and laboratory diagnostics.

BDX's moat is further strengthened by continuous investments in research and development as well as strategic acquisitions. These factors enable the company to offer innovative solutions and differentiate itself from the competition.

Compared to its competitors, BDX has a solid, but not insurmountable moat. Companies like Medtronic and Johnson & Johnson also have strong market positions and heavily invest in innovation and expansion, strengthening their own moats.

Overall, BDX has a respectable competitive advantage, but they need to continue investing in innovation and market adaptation to maintain and expand their position.

Revenue growth: 5.2% (2024) Profit growth: 4.8% (2024) Research and Development (R&D) expenses: 7.5% of revenue (2024)

Becton, Dickinson and Company (BD) recorded solid revenue growth of 5.2% in 2024. This indicates that the company is able to maintain its market position and possibly expand it further. The profit growth of 4.8% during the same period supports this positive development.

The company continues to invest heavily in research and development, accounting for 7.5% of revenue. These investments are crucial for BD's long-term innovation capabilities and competitiveness, especially in a rapidly evolving healthcare sector.

Additionally, BD has made strategic acquisitions in recent years to expand its product portfolio and enter new markets. These measures could further strengthen the company's future growth potential.

Overall, BD demonstrates stable financial performance and strategic direction, making it a potentially good investment, especially for investors interested in long-term growth.

Dividend yield: 1.4% (estimated for 2025)
Dividend history: 50 years of continuous payouts

Becton, Dickinson and Company (BD) is known for its reliable dividend policy. Over the past 50 years, the company has consistently distributed dividends, indicating strong financial stability and solid profitability.

The dividend yield of approximately 1.4% in 2025 reflects a moderate payout policy aimed at providing shareholders with a regular return while retaining enough capital for reinvestment and company growth.

BD has a long tradition of increasing dividends, underscoring confidence in its future payout ability. Analysts expect the company to continue maintaining its dividend policy based on its stable market position and continuous earnings.